ScripSutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c
Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
ScripAtara Biotherapeutics’ troubles have deepened as, in the space of less than a week, the US Food and Drug Administration followed a complete response letter (CRL) with a clinical hold on its active inv
Pink SheetThe US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will